Skip to main content
Top
Published in: Supportive Care in Cancer 9/2008

01-09-2008 | Original ARticle

Changes in quality of life and its related factors in liver cancer patients receiving stereotactic radiation therapy

Authors: Shiow-Ching Shun, Jeng-Fong Chiou, Yeur-Hur Lai, Po-Jui Yu, Lin-Lin Wei, Jo-Ting Tsai, Chung-Yu Kao, Ya-Li Hsiao

Published in: Supportive Care in Cancer | Issue 9/2008

Login to get access

Abstract

Purpose

Due to the increasing use of stereotactic radiotherapy (SRT) in treating advanced liver cancer patients, the purpose of this longitudinal study was to explore the changes and factors related to quality of life (QOL) in patients receiving SRT treatment.

Materials and methods

Liver cancer patients receiving SRT in northern Taiwan were recruited. The patients were followed up during the baseline pre-SRT and the first 6 weeks of SRT (T0 to T6) in assessing functional status and symptom severity, while depression, selected laboratory data, and QOL were assessed every 3 weeks (T0, T3, and T6). Generalized estimating equations (GEE) analysis was used to explore the significant factors related to the change in QOL.

Results

Ninety-nine patients with advanced liver cancer completed seven interviews. The results showed that QOL during SRT was moderate and relatively stable. Performance functional status, depression, the level of albumin, and overall symptom severity were significantly associated with changes in QOL. A further analysis of the relationships between individual symptom severity and QOL revealed that fatigue, lack of appetite, pain, and nausea were the symptoms most affecting QOL across the 6 weeks of SRT.

Conclusion

Liver cancer patients had stable and moderate levels of QOL during SRT. Factors related to QOL across the 6 weeks were multi-dimensional. Both overall symptom severity and selected individual symptoms were important to patients' QOL. These factors should all be carefully assessed and clinically treated to enhance liver cancer patients' QOL during SRT.
Literature
1.
go back to reference Ballinger GA (2004) Using generalized estimating equations for longitudinal data analysis. Organ Res Methods 7:127–149CrossRef Ballinger GA (2004) Using generalized estimating equations for longitudinal data analysis. Organ Res Methods 7:127–149CrossRef
2.
go back to reference Ben-Josef E, Lawrence TS (2005) Radiotherapy for unresectable hepatic malignancies. Semin Radiat Oncol 15:273–278PubMedCrossRef Ben-Josef E, Lawrence TS (2005) Radiotherapy for unresectable hepatic malignancies. Semin Radiat Oncol 15:273–278PubMedCrossRef
3.
go back to reference Bianchi G, Loguercio C, Sgarbi D, Abbiati R, Brunetti N, De Simone T, Zoli M, Marchesini G (2003) Reduced quality of life of patients with hepatocellular carcinoma. Dig Liver Dis 35:46–54PubMedCrossRef Bianchi G, Loguercio C, Sgarbi D, Abbiati R, Brunetti N, De Simone T, Zoli M, Marchesini G (2003) Reduced quality of life of patients with hepatocellular carcinoma. Dig Liver Dis 35:46–54PubMedCrossRef
4.
go back to reference Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5–S16PubMedCrossRef Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5–S16PubMedCrossRef
5.
go back to reference Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A:1135–1141PubMedCrossRef Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A:1135–1141PubMedCrossRef
6.
go back to reference Dagnelie PC, Pijls-Johannesma MC, Lambin P, Beijer S, De Ruysscher D, Kempen GI (2007) Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy. Ann Oncol 18:940–944PubMedCrossRef Dagnelie PC, Pijls-Johannesma MC, Lambin P, Beijer S, De Ruysscher D, Kempen GI (2007) Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy. Ann Oncol 18:940–944PubMedCrossRef
8.
go back to reference Dirix P, Nuyts S, Vander Poorten V, Delaere P, Van den Bogaert W (2007) The influence of xerostomia after radiotherapy on quality of life: Results of a questionnaire in head and neck cancer. Support Care Cancer, (in press) Dirix P, Nuyts S, Vander Poorten V, Delaere P, Van den Bogaert W (2007) The influence of xerostomia after radiotherapy on quality of life: Results of a questionnaire in head and neck cancer. Support Care Cancer, (in press)
9.
go back to reference Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG (1996) Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 14:171–175PubMed Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG (1996) Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 14:171–175PubMed
10.
go back to reference Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N, van Zandwijk N, Di Maio M, Martelli O, De Marinis F (2004) Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 15:419–426PubMedCrossRef Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N, van Zandwijk N, Di Maio M, Martelli O, De Marinis F (2004) Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 15:419–426PubMedCrossRef
11.
go back to reference Hawkins MA, Dawson LA (2006) Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106:1653–1663PubMedCrossRef Hawkins MA, Dawson LA (2006) Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106:1653–1663PubMedCrossRef
12.
go back to reference Hawkins MA, Eccles C, Lockwood G, Cummings B, Ringash J, Knox JJ, Sherman M, Greig P, Gallinger S, Dawson LA (2005) Preliminary results of a phase I study of stereotactic radiotherapy for unresectable primary and metastatic liver cancer. J Clin Oncol (Meeting Abstracts) 23:4127 Hawkins MA, Eccles C, Lockwood G, Cummings B, Ringash J, Knox JJ, Sherman M, Greig P, Gallinger S, Dawson LA (2005) Preliminary results of a phase I study of stereotactic radiotherapy for unresectable primary and metastatic liver cancer. J Clin Oncol (Meeting Abstracts) 23:4127
13.
go back to reference King MT, Dobson AJ, Harnett PR (1996) A comparison of two quality-of-life questionnaires for cancer clinical trials: the functional living index—cancer (FLIC) and the quality of life questionnaire core module (QLQ-C30). J Clin Epidemiol 49:21–29PubMedCrossRef King MT, Dobson AJ, Harnett PR (1996) A comparison of two quality-of-life questionnaires for cancer clinical trials: the functional living index—cancer (FLIC) and the quality of life questionnaire core module (QLQ-C30). J Clin Epidemiol 49:21–29PubMedCrossRef
14.
go back to reference Lai YH, Shun SC, Hsiao YL, Chiou JF, Wei LL, Tsai JT, Kao CY (2007) Fatigue experiences in hepatocellular carcinoma patients during six weeks of stereotactic radiotherapy. Oncologist 12:221–230PubMedCrossRef Lai YH, Shun SC, Hsiao YL, Chiou JF, Wei LL, Tsai JT, Kao CY (2007) Fatigue experiences in hepatocellular carcinoma patients during six weeks of stereotactic radiotherapy. Oncologist 12:221–230PubMedCrossRef
15.
go back to reference Lips I, Dehnad H, Kruger AB, van Moorselaar J, van der Heide U, Battermann J, van Vulpen M (2007) Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 69:656–661PubMed Lips I, Dehnad H, Kruger AB, van Moorselaar J, van der Heide U, Battermann J, van Vulpen M (2007) Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 69:656–661PubMed
16.
17.
go back to reference Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef
18.
go back to reference Peppercorn J, Herndon J 2nd, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E (2005) Quality of life among patients with stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer 104:1580–1589PubMedCrossRef Peppercorn J, Herndon J 2nd, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E (2005) Quality of life among patients with stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer 104:1580–1589PubMedCrossRef
19.
go back to reference Rustoen T (1995) Hope and quality of life, two central issues for cancer patients: a theoretical analysis. Cancer Nurs 18:355–361PubMed Rustoen T (1995) Hope and quality of life, two central issues for cancer patients: a theoretical analysis. Cancer Nurs 18:355–361PubMed
20.
go back to reference Rustoen T, Moum T, Padilla G, Paul S, Miaskowski C (2005) Predictors of quality of life in oncology outpatients with pain from bone metastasis. J Pain Symptom Manage 30:234–242PubMedCrossRef Rustoen T, Moum T, Padilla G, Paul S, Miaskowski C (2005) Predictors of quality of life in oncology outpatients with pain from bone metastasis. J Pain Symptom Manage 30:234–242PubMedCrossRef
21.
go back to reference Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring the quality of life of cancer patients: the Functional Living Index—Cancer: development and validation. J Clin Oncol 2:472–483PubMed Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring the quality of life of cancer patients: the Functional Living Index—Cancer: development and validation. J Clin Oncol 2:472–483PubMed
22.
23.
go back to reference Shang E, Weiss C, Post S, Kaehler G (2006) The influence of early supplementation of parenteral nutrition on quality of life and body composition in patients with advanced cancer. J Parenter Enteral Nutr 30:222–230CrossRef Shang E, Weiss C, Post S, Kaehler G (2006) The influence of early supplementation of parenteral nutrition on quality of life and body composition in patients with advanced cancer. J Parenter Enteral Nutr 30:222–230CrossRef
24.
go back to reference Shioyama Y, Nakamura K, Anai S, Sasaki T, Ooga S, Saku M, Urashima Y, Yoshitake T, Toba T, Terashima H, Honda H (2005) Stereotactic radiotherapy for lung and liver tumors using a body cast system:setup accuracy and preliminary clinical outcome. Radiat Med 23:407–413PubMed Shioyama Y, Nakamura K, Anai S, Sasaki T, Ooga S, Saku M, Urashima Y, Yoshitake T, Toba T, Terashima H, Honda H (2005) Stereotactic radiotherapy for lung and liver tumors using a body cast system:setup accuracy and preliminary clinical outcome. Radiat Med 23:407–413PubMed
25.
go back to reference Visser MR, Smets EM (1998) Fatigue, depression and quality of life in cancer patients: how are they related. Support Care Cancer 6:101–108PubMedCrossRef Visser MR, Smets EM (1998) Fatigue, depression and quality of life in cancer patients: how are they related. Support Care Cancer 6:101–108PubMedCrossRef
26.
go back to reference Yamashita H, Nakagawa K, Shiraishi K, Tago M, Igaki H, Nakamura N, Sasano N, Siina S, Omata M, Ohtomo K (2007) Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma:retrospective study. J Gastroenterol Hepatol 22:523–527PubMedCrossRef Yamashita H, Nakagawa K, Shiraishi K, Tago M, Igaki H, Nakamura N, Sasano N, Siina S, Omata M, Ohtomo K (2007) Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma:retrospective study. J Gastroenterol Hepatol 22:523–527PubMedCrossRef
27.
go back to reference Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121–130PubMedCrossRef Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121–130PubMedCrossRef
28.
go back to reference Zhou ZH, Liu LM, Chen WW, Men ZQ, Lin JH, Chen Z, Zhang XJ, Jiang GL (2007) Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol 80:194–201PubMedCrossRef Zhou ZH, Liu LM, Chen WW, Men ZQ, Lin JH, Chen Z, Zhang XJ, Jiang GL (2007) Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol 80:194–201PubMedCrossRef
Metadata
Title
Changes in quality of life and its related factors in liver cancer patients receiving stereotactic radiation therapy
Authors
Shiow-Ching Shun
Jeng-Fong Chiou
Yeur-Hur Lai
Po-Jui Yu
Lin-Lin Wei
Jo-Ting Tsai
Chung-Yu Kao
Ya-Li Hsiao
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 9/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0384-y

Other articles of this Issue 9/2008

Supportive Care in Cancer 9/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine